指南与共识类风湿关节炎

EULAR 2016年类风湿关节炎管理建议更新

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
指南 / 共识 · Ann Rheum Dis · 2017-03-06

基于3项系统文献综述,国际工作组制定4条总体原则和12条推荐,涵盖csDMARDs、糖皮质激素、bDMARDs及tsDMARDs的使用策略。推荐以MTX(快速加量至25mg/周)联合短期GC为起始策略,目标为3个月内改善>50%、6个月内达标;失败后根据预后不良标志物分层选择csDMARDs、bDMARDs或JAK抑制剂。

要点

  • 起始治疗推荐MTX快速加量至25mg/周联合短期GC,3个月改善>50%、6个月达标。
  • 无预后不良标志物者,失败后换用或加用另一种csDMARDs(联合短期GC)。
  • 有预后不良标志物者,在csDMARDs基础上加用bDMARD或JAK抑制剂。

核心结论

  • EULAR 2016更新推荐以MTX联合短期GC为起始策略,追求3个月内改善>50%和6个月内达标。
  • 治疗失败后根据预后不良标志物分层,选择csDMARDs、bDMARDs或tsDMARDs。
  • 持续缓解后可逐渐减量bDMARDs。

研究设计与样本

  • 国际工作组基于3项系统文献综述制定4条总体原则和12条推荐(2013版为3条和14条)。
  • 推荐每条均提供证据等级和工作组同意度,均大多非常高。

主要发现

  • 起始策略推荐MTX快速加量至25mg/周联合短期GC,目标3个月内改善>50%、6个月内达标。
  • 无预后不良标志物时,失败后建议换用或加用另一种csDMARDs(联合短期GC)。
  • 有预后不良标志物(自身抗体、高疾病活动度、早期侵蚀、2种csDMARDs失败)时,加用任何bDMARD或JAK抑制剂。
  • bDMARD或JAK抑制剂失败后,推荐换用任何其他bDMARD或tsDMARD。
  • 持续缓解患者可逐渐减量bDMARDs。

关键数值与推荐

  • MTX快速加量至25mg/周联合短期GC,目标3个月内改善>50%、6个月内达标。
  • 预后不良标志物包括自身抗体、高疾病活动度、早期侵蚀、2种csDMARDs失败。
  • 持续临床缓解定义采用ACR-EULAR布尔或指数标准。

临床怎么用

  • 对活动性RA患者,起始MTX快速加量联合短期GC,密切监测3个月和6个月达标情况。
  • 治疗失败时评估预后不良标志物,无标志物者换用/加用csDMARDs,有标志物者加用bDMARD或JAK抑制剂。
  • 达到持续缓解后可考虑逐渐减量bDMARDs。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017. PMID: 28264816. doi:10.1136/annrheumdis-2016-210715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。